Search details
1.
Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial.
Nephrol Dial Transplant
; 35(12): 2103-2111, 2020 12 04.
Article
in English
| MEDLINE | ID: mdl-31495881
2.
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Diabetes Obes Metab
; 22(7): 1151-1156, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32115840
3.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation
; 137(2): 119-129, 2018 01 09.
Article
in English
| MEDLINE | ID: mdl-28904068
4.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med
; 375(4): 323-34, 2016 Jul 28.
Article
in English
| MEDLINE | ID: mdl-27299675
5.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 39(5): 363-370, 2018 02 01.
Article
in English
| MEDLINE | ID: mdl-29020355
6.
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
JAMA
; 322(12): 1155-1166, 2019 Sep 24.
Article
in English
| MEDLINE | ID: mdl-31536101
7.
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Kidney Int
; 93(1): 231-244, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28860019
8.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med
; 373(22): 2117-28, 2015 11 26.
Article
in English
| MEDLINE | ID: mdl-26378978
9.
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Diabetes Obes Metab
; 20(12): 2768-2777, 2018 12.
Article
in English
| MEDLINE | ID: mdl-29961998
10.
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Stroke
; 48(5): 1218-1225, 2017 05.
Article
in English
| MEDLINE | ID: mdl-28386035
11.
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension.
Diabetes Obes Metab
; 19(11): 1620-1624, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28387058
12.
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Diabetes Obes Metab
; 19(2): 266-274, 2017 02.
Article
in English
| MEDLINE | ID: mdl-27762093
13.
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
Eur Heart J
; 37(19): 1526-34, 2016 May 14.
Article
in English
| MEDLINE | ID: mdl-26819227
14.
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Diabetologia
; 59(9): 1860-70, 2016 09.
Article
in English
| MEDLINE | ID: mdl-27316632
15.
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Diabetes Obes Metab
; 18(10): 1045-9, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27265507
16.
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Circulation
; 129(5): 587-97, 2014 Feb 04.
Article
in English
| MEDLINE | ID: mdl-24334175
17.
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Cardiovasc Diabetol
; 14: 154, 2015 Dec 23.
Article
in English
| MEDLINE | ID: mdl-26701110
18.
Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
Circulation
; 138(15): 1599-1601, 2018 10 09.
Article
in English
| MEDLINE | ID: mdl-30354516
19.
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.
Br J Clin Pharmacol
; 78(6): 1407-18, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-24964723
20.
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Cardiovasc Diabetol
; 12: 129, 2013 Sep 05.
Article
in English
| MEDLINE | ID: mdl-24007456